Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma  by Lustgarten, Daniel E. Schwed et al.
469Journal of Thoracic Oncology  •  Volume 8, Number 4, April 2013
Purpose: Thymidylate synthase (TS) is a potential predictor of 
outcome after pemetrexed (Pem) in patients with malignant pleural 
mesothelioma (MPM), and assays measuring TS levels are commer-
cially marketed. The goal of this study was to further evaluate the 
value of TS and to study another potential biomarker of response, the 
enzyme, folyl-polyglutamate synthase (FPGS), which activates Pem 
intracellularly.
Methods: Levels of TS and FPGS were semi-quantitatively deter-
mined immunohistochemically using H-scores on tissue samples 
from 85 MPM patients receiving Pem as primary therapy. H-score 
was correlated with radiographic disease control rate (DCR), time to 
progression (TTP) and overall survival (OS). In addition, expression 
levels of TS and FPGS in MPM cell lines were determined using 
immunoblotting and correlated with their sensitivity to Pem-induced 
cell death.
Results: H-scores from patients with disease control versus progres-
sive disease showed extensive overlap. There were no significant cor-
relations of DCR, TTP, or OS to either TS levels (p = 0.73, 0.93, and 
0.59, respectively), FPGS levels (p = 0.95, 0.77, and 0.43, respec-
tively) or the ratio of FPGS/TS using the median scores of each test 
as cutoffs. There was no correlation between TS or FPGS expression 
and chemosensitivity of mesothelioma cells to Pem in vitro.
Conclusions: Although previous retrospective data suggest that TS 
and FPGS expression might be potential markers of Pem efficacy in 
MPM, our data indicate these markers lack sufficient predictive value 
in individual patients and should not be used to guide therapeutic 
decisions in the absence of prospective studies.
Key Words: Thymidylate synthase, Malignant pleural mesothe-
lioma, Pemetrexed.
(J Thorac Oncol. 2013;8:469-477)
Malignant pleural mesothelioma (MPM) is a rare, deadly cancer associated with exposure to asbestos. Without 
treatment, patients with MPM have a median survival of 
approximately 9 months. In a landmark phase III trial by 
Vogelzang et al.,1 pemetrexed (Pem) and cisplatin improved 
outcomes compared with cisplatin alone, with commensurate 
improvement in progression free survival. Overall survival 
(OS) improved by 11 weeks when compared with cisplatin 
alone. This doublet has become the standard of care when sys-
temic therapy is used.
Pem is an antifolate agent that inhibits multiple folate-
dependent enzymes. The main target of Pem is thought to be 
thymidylate synthase (TS); to a lesser extent, glycinamide 
ribonucleotide formyltransferase, dihydrofolate reductase 
and 5-aminoimidazole-4-carboxamide ribonucleotide for-
myltransferase are also considered targets.2 As a folic acid 
analog, Pem enters the cell through the reduced folate car-
rier and the folate receptor-α. Once inside the cell, its activity 
is dependent on glutamation. Pem is poly-glutamated by the 
key enzyme folyl-polyglutamate synthase (FPGS). This step 
increases the intracellular retention of Pem and the affinity for 
its intracellular targets by 50- to 100-fold.2
Although the use of Pem in combination with 
platinum has fostered a major advance in the treatment of 
MPM, the objective radiological response rate is only approxi-
mately 40%.1 Hence, the majority of patients who receive 
the drug are exposed to its toxic side effects (and consi-
derable costs) without radiographic or clear clinical benefit. 
Therefore, finding biomarkers that will identify the 
population of patients most likely to benefit from Pem is an 
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important goal as we enter the era of personalized therapeutic 
oncology.
In vitro data support a connection between TS expres-
sion and Pem response. In colon, breast and lung cancer cell 
lines, higher gene and protein expression of TS has been 
associated with resistance to Pem.3,4 Induction of resistance 
to Pem in a colon cancer cell line was associated with TS over-
expression.5 Three phase III clinical trials have shown Pem to 
be more efficacious in patients with adenocarcinoma of the 
lung as opposed to those with squamous cell histology.6–8 TS 
expression has been found to be lower in adenocarcinoma than 
squamous cells.9 In addition, low TS levels have been shown 
to predict better outcomes in patients with non-squamous 
non–small-cell lung cancer treated with Pem.10
Three recent retrospective studies showed a statistical 
association between TS expression measured by immuno-
histochemistry (IHC) and response to Pem in patients with 
MPM.11–13 The later study also showed that patients with high 
FPGS had better tumor responses and improved disease con-
trol rate. However, the clinical utility of measuring TS expres-
sion or FPGS to select patients for treatment with Pem has yet 
to be verified in prospective clinical trials.
The goal of our retrospective study was to validate these 
findings in a well-characterized set of MPM patients treated 
with Pem. As it is postulated that TS and FPGS have an inverse 
relationship with regard to Pem sensitivity (decreased TS lev-
els have been proposed to predict response to Pem therapy,14 
although increased FPGS levels have been proposed to pre-
dict sensitivity to Pem therapy),15,16 we also tested whether the 
ratio of FPGS/TS expression could predict clinical responses 
to Pem in patients with MPM.
PATIENTS AND METHODS
Study Population
Patient samples were obtained from three sites: the 
Fondazione IRCCS Policlinico San Matteo in Pavia, Italy (69 
cases); the Sir Charles Gairdner Hospital in Perth, Australia 
(12 cases); and the Hospital of the University of Pennsylvania 
in Philadelphia (four cases). Patients were included if they had 
a diagnosis of MPM, received at least one cycle of a front-
line Pem-containing chemotherapy regimen, and had tissue 
available for immunohistochemical analysis. Patients receiv-
ing adjuvant or neoadjuvant Pem in the setting of surgical 
resection were excluded. All patients were followed with a 
computed tomography of the chest every 3 months during 
treatment and up to 2 years after chemotherapy was com-
pleted. Patients who survived greater than 2 years had imag-
ing every 6 months.
The primary end point was the association between 
TS, FPGS, and FPGS/TS expression measured by IHC and: 
(1) time to progression (TTP), (2) OS, and (3) best-achieved 
radiographic response. Radiographic response was measured 
according to the modified response evaluation criteria in solid 
tumors (Response Evaluation Criteria in Solid Tumors) for 
MPM.17 Patients were classified as having “disease control” 
if the best response was complete response, partial response, 
or stable disease. Otherwise, they were classified as having 
progressive disease.
Immunohistochemistry
IHC was performed on formalin-fixed, paraffin-embed-
ded tissue. Samples were first deparaffinized with xylene and 
rehydrated in serial dilutions of ethanol. Antigen unmask-
ing was performed by heat-induced epitope retrieval method 
with a 10 mM sodium citrate solution buffered at pH 6.0. The 
samples were then incubated with the primary antibody [anti-
thymidylate synthase Ab clone TS106 (Invitrogen, Carlsbad, 
CA) at a dilution of 1:100 for 30 minutes at room temperature, 
and an anti-FPGS monoclonal Ab18 provided by Eli-Lilly and 
Company (Indianapolis, IN) at a dilution of 1:1500 at 4°C over-
night. Appropriate treatment with 3% hydrogen peroxide and 
DAKO serum-free protein block were performed before incu-
bation with the primary antibody. DAKO antimouse horserad-
ish peroxidase polymer solution was used for the detection of 
the primary antibody and diamino benzidine was used as sub-
strate. The germinal centers of normal human tonsils were used 
as a 3+ positive control for TS (Fig. 1A) and normal human 
kidney (Fig. 1C) was used as a 3+ positive control for FPGS. To 
assess nonspecific staining, negative controls were stained with 
isotype control monoclonal antibodies for the anti-TS (Fig. 1B) 
and anti-FPGS antibodies (Fig. 1D) then processed as above. 
Both antibodies showed high specificity on immunoblotting 
(i.e., see Fig. 4, FPGS data not shown). As they were monoclo-
nal antibodies, blocking peptides were not available.
H Score
To determine the H score, the intensity of the cytoplasmic 
and nuclear staining was compared with a strong positive con-
trol and given an intensity score: 0 – no staining, 1 – mild inten-
sity, 2 – moderate intensity, 3 – intensity equal to or greater than 
the positive control. The percentage of cells with each intensity 
score was estimated. The H score was obtained by adding the 
product of the intensity score multiplied by the percentage of 
cells staining at that intensity, thus the H score ranged from 0 
to 300.19 All samples were scored by a single lung pathologist 
(C.D.) blinded to the patient’s clinical outcome. The H-score 
was verified by a second pathologist (L.L.) in the first 40 cases 
and showed high intraobserver concordance.
In Vitro Experiments with Cell Lines
Nine human mesothelioma cell lines were examined 
for sensitivity to Pem using a colorimetric MTT assay. To 
perform MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide] assays to estimate cell numbers, 
cells were plated in triplicate on 96-well plates (5000 cells 
per well in their respective culture medium) and were 
treated with various concentrations (ranging from 0.001 
to 100 µM) of pemetrexed. Cell viability was assessed 72 
hours after treatment by developing the reaction assay per 
manufacturer’s instruction (Promega, Madison, WI). The 
IC
50
 values of Pem (the concentration of Pem inhibiting 
tumor cell growth by 50% in comparison with the untreated 
control) in our human mesothelioma cell lines were 
determined from these MTT results.
The expression level of TS and FPGS was determined 
by immunoblotting. Human mesothelioma cell lines were 
grown in T75 tissue culture flask until they reached 90 to 100% 
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confluence. The cells were then harvested and lysed in ice-
cold lysis buffer (50 mM Tris–HCL, pH 7.4, 150 mM NaCL, 
5 mM ethylenediaminetetraacetic acid, 1% Nonidet P-40, 
and protease inhibitor cocktail tablets [Roche Diagnostics, 
Indianapolis, IN] with 1 mM phenylmethyl sulfonyl fluoride). 
Equal amounts of protein from whole cell lysate from each 
sample were electrophoresed on 4 to 12% NuPAGE Novex 
Tris Acetate Mini Gels (Invitrogen) and transferred onto nitro-
cellulose membranes. Monoclonal anti-β-actin antibody (pur-
chased from Sigma, St. Louis, MO). The Anti-TS antibody 
(clone TS106) was used at a concentration of 2 µg/ml (1:100 
dilution). The FPGS antibody (see above) was used at a con-
centration of 0.25 µg/ml (1:5000 dilution).
The human OK4, OK5, OK6, and OK7 MPM cell 
lines were provided by Dr. Claire Verschaegen (University of 
Vermont). The I-45 and MSTO-211H MPM lines were pur-
chased from the American Tissue Type Collection (Manassas, 
VA). The human Pt108, REN, LRK, and M30 MPM lines were 
derived from patient samples at the University of Pennsylvania.
Statistical Analysis
OS was calculated from the time the first cycle with a 
Pem-containing regimen was initiated to the time of death. 
TTP was calculated from the time the first cycle was initi-
ated to the time disease progression and was documented 
according to modified Response Evaluation Criteria in Solid 
Tumors criteria. OS and TTP were evaluated using standard 
Kaplan–Meier curves, and a log-rank test was used to com-
pare survival between groups. Hazard ratios were obtained 
using a Cox proportional hazards regression model. A χ2 test 
was used to analyze the association between categorical vari-
ables. STATA (version 11; STATA Corp LP, College Station, 
TX) was used for all analysis, and statistical significance was 
set at a p value of 0.05 or lesser for all tests.
RESULTS
Clinical Characteristics
Eighty-five patients with MPM who were treated with 
Pem were included; 75 received Pem plus a platinum agent 
and 10 received Pem alone. Samples with fewer than 100 
malignant cells were excluded from the analysis. The char-
acteristics of the study population are summarized in Table 1.
The clinical outcomes are summarized in Table 1 and are 
similar to other studies.1,12 The overall disease control rate was 
69%, progressive disease was documented in 31%. Median 
TTP was 6.8 months. Median OS time was 13 months.
The effects of clinical characteristics on outcomes are 
also shown in Table 1. Gender was not predictive of TTP or 
OS. A nonepithelioid histology was associated with shorter 
survival (hazard ratio: 3.03; 95% confidence intervals: 1.64–
5.62; p < 0.001) but not with shortened TTP. Age above 65 
years was associated with shorter TTP (p = 0.02), but not with 
worse survival.
Relationship of Thymidylate 
Synthase to Clinical Outcomes
Of 85 patients, 78 samples were available for TS staining 
and analysis (some sections were not included due to technical 
reasons). TS staining was mostly nuclear with variable 
cytoplasmic expression (Fig. 1). In virtually all patients, some 
degree of staining was seen with a range of H-scores from 
10 to 190. The level of TS expression detected by IHC followed 
a normal distribution (Fig. 2A). The median H-score was 105.
We plotted the H-score from patients with disease pro-
gression versus disease control. As shown in Figure 2C, there 
was extensive overlap between groups with both having the 
same median score of 105.
FIGURE 1.  Examples of immunohistochemical staining on tissues. (A) Human tonsil stained with anti-thymidylate synthase Ab 
clone TS106 (Invitrogen) shows strongly (3+) positive lymphocyte staining. (B) Human tonsil stained with a control antibody 
shows no staining (negative control). (C) Human Kidney stained with the anti-FPGS antibody shows strong (3+ staining of the 
tubules. (D) Human kidney stained with control antibody shows no staining. (E) MPM tissue sample stained with anti-TS anti-
body showing an H score of 20. (F) MPM tissue sample stained with anti-TS antibody showing an H score of 90. (G) MPM tissue 
sample stained with anti-TS antibody showing an H score of 130. (H) MPM tissue sample stained with anti-TS antibody showing 
an H score of 190. FPGS, folyl-polyglutamate synthase; MPM, malignant pleural mesothelioma; TS, thymidylate synthase.
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We next used the median H-score of 105 to classify 
samples as having “high” or “low” TS expression (Table 
2). When comparing high TS levels to low TS levels, we 
observed no differences in disease control rates (DCR) (p 
= 0.73) (Table 2). We performed the same analysis in the 
subgroup of patients with epithelioid histology and found 
similar results. Although there was a numerically longer 
median TTP (8 versus 6 months; p = 0.93) and OS (14 versus 
11.25 months; p = 0.59) in the patients with low TS scores 
compared with higher TS scores these differences were not 
statistically significant. The Kaplan–Meier curves are shown 
in Figure 3A,B (on-line only).
Relationship of Folyl-Polyglutamate 
Synthase to Clinical Outcomes
Of 85 patients, 74 had adequate samples available for 
FPGS analysis due to technical reasons. FPGS was detected 
in almost all patients (72 out of 74), again with a normal dis-
tribution of H-scores (Fig. 2B). Staining was both nuclear and 
cytoplasmic (Fig. 1C). The median H-score was 120 (ranges, 
0–285).
We plotted the H-scores from patients with disease pro-
gression versus disease control. As shown in Figure 2D, exten-
sive overlap existed between the groups: the median H-score 
was 120 in patients with disease progression and 130 in those 
with disease control.
Using the median H-score of 120, samples were 
categorized as having “high” or “low” FPGS expression 
(Table 2). We did not find a significant association between 
high and low FPGS expression and median TTP (p = 0.77), 
median OS (p = 0.43), or DCR (p = 0.95). The Kaplan–Meier 
curves are shown in Figure 3C,D (on-line only).
FPGS/TS Ratio
The ratio of FPGS/TS was calculated by dividing the 
FPGS H-score by the TS H-score for each patient. The data 
appeared normally distributed. The median ratio was 1.17 and 
this value was used to classify samples as having high or low 
FPGS/TS ratios (Table 2). In patients with a high FPGS/TS ratio 
there was a higher TTP (7.5 versus 6 months; p = 0.10), OS 
(13 versus 12 months; p = 0.43), and DCR (76.3 versus 64.9%; 
p = 0.27), but these differences were not statistically significant.
FIGURE 2.  Levels of TS and FPGS expression detected by IHC. (A) frequency distribution of H scores for TS staining in all tumor 
samples. (B) frequency distribution of H scores for FPGS staining in all tumor samples. (C) Plot of H scores for anti-TS staining 
versus best radiographic responses comparing patients with progressive disease versus those with disease control (stable disease 
plus partial response). (D) Plot of H scores for anti-FPGS staining versus best radiographic responses comparing patients with 
progressive disease versus those with disease control (stable disease plus partial response). FPGS, folyl-polyglutamate synthase; 
IHC, immunohistochemistry; TS, thymidylate synthase.
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Correlation of TS and FPGS Expression 
with In Vitro Chemosensitivity of Human 
Mesothelioma Cells to Pemetrexed
Given the lack of correlation between TS expression 
and the clinical response to Pem, we tested whether such 
a correlation existed in in vitro. Nine human mesotheli-
oma cell lines were treated with varying concentrations of 
Pem, ranging from 0.001 to 100 µM, and cell viability was 
assessed 72 hours after treatment. The 50% inhibitory con-
centration (IC
50
) values were then determined in each cell 
line and correlated with the TS expression as determined 
by immunoblotting, (Supplemental Table 1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A388 and Fig. 
4). Consistent with our clinical data, we did not observe any 
correlation between TS expression and chemosensitivity of 
mesothelioma cells to Pem in vitro. We performed similar in 
vitro studies evaluating FPGS expression by immunoblotting 
and again observed no correlation with IC
50
 values of Pem 
for each cell line (data not shown).
DISCUSSION
The clinical data supporting the relationship between 
TS and Pem sensitivity has largely been indirect; based on 
relatively small retrospective studies that showed an association 
between lower levels of TS expression and Pem efficacy in 
mesothelioma and lung cancer.20 Three recent observational 
studies11–13 demonstrated a statistical association between 
intratumoral TS expression and Pem efficacy in patients with 
MPM. Table 3 compares these studies to ours. In all studies, 
TS levels were semi-quantitatively measured by IHC using the 
same H-score metric that we used. In the Righi study,11 the 
median H-score was 90 and when used as a cutoff, a significant 
correlation between TS levels and both TTP and OS was seen. 
In this study, TS but not ERCC1 expression was associated 
with TTP and OS. No data on response rates were provided. 
It should be noted that the overall survival of the entire group 
(20.9 months) was much longer than the 13 months reported in 
the large phase III Pem trial by Vogelzang,1 the Zucali study,12 
and our cohort, suggesting the selection of a “healthier” and 
FIGURE 3.  Kaplan–Meier (KM) survival curves. (A) Overall KM survival according to TS expression, (B) KM plot of time to pro-
gression according to TS expression. (C) Overall KM survival according to FPGS expression, (D) KM plot of time to progression 
according to FPGS expression. FPGS, folyl-polyglutamate synthase; KM, TS, thymidylate synthase.
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likely less representative cohort of patients than is usually 
treated. In the Zucali study,12 the median H-score was very 
low (a value of 21). The progression-free survival (PFS) and 
OS survival were 7 and 13 months respectively, with a disease 
control rate of 78%, much more similar to our data and to 
other data cited in the literature. When the median H score 
was used as a cutoff, statistically significant differences in 
disease control rates (92 versus 73%), median PFS (7 versus 
6 months) and OS (18 versus 9 months) were observed based 
on TS levels. In the Christoph study,13 the median H-score was 
very high (a value of 210). Their OS was much longer (23.3 
months) compared with other studies, but similar to that seen 
in the Righi study. They found that median TS was associated 
with statistically significant differences in OS, but not PFS, 
objective response rate (OR), or DCR.
Our median H-score was 105, similar to that seen by 
Righi, but clearly different from that appreciated by Zucali or 
Christoph11–13 (Table 3). We observed an overall DCR of 69%, 
a median TTP of 6.8 months, and a median OS of 13 months 
(outcomes similar to those of Zucali and previous studies, and 
the established literature.1 Although the median TTP (8 versus 
6 months) and OS (14 versus 11 months) were longer in our 
low TS versus high TS group, these differences did not reach 
statistical significance. Other cutoffs, beside the median score, 
FIGURE 4.  Immunoblot of mesothelioma cell lines cor-
related with sensitivity to pemetrexed. Equal amounts of 
protein lysates from nine human mesothelioma cell lines were 
loaded onto an sodium dodecyl sulfate gel, immunoblotted, 
and reacted with the anti-TS antibody (top panel) or with an 
anti-actin antibody (bottom panel) to assure equal loading. 
Clear variations in TS content were noted. The same nine 
cell lines were treated with varying concentrations of Pem, 
ranging from 0.001 to 100 µM, and cell viability was assessed 
72 hours after treatment. The 50% inhibitory concentrations 
(IC50) values were then determined in each cell line. There 
was no clear correlation with sensitivity to Pem and the TS 
expression level as observed in the immunoblot. TS, thymi-
dylate synthase.
TABLE 1.  Characteristics of Patients with MPM Treated with Pemetrexed
Clinical characteristic n % Median TTP Median OS
Total 85
Gender
Male 55 64.7 7.0 months 13.25
Female 30 35.3 6.0 months 11
(p) (0.71) (0.76)
Age (median / range) 68 / (35–85)
Less than 65 years 32 37.7 10.75 months 14
Greater than or equal to 65 years 53 62.3 6 months 12
(p) (0.02) (0.49)
Histology 70 / 85
Epithelial 50 71.4 8.0 months 17 months
Nonepithelial 
(Sarcomatoid) 
(Biphasic)
20 
(11) 
(9)
28.6 
(15.7) 
(12.9)
5.5 months 10 months
Treatment
Pemetrexed PLUS platinum 75 88
Pemetrexed alone 10 12
(p) (0.04) (<0.001)
NA 15/85
Radiographic response (modified 
RECIST)
83
Disease control (CR, PR, or SD) 57 68.7 10 months 18 months
Progressive disease 26 31.3 4 months 8.5 months
(p) (<0.0001) (<0.0001)
Median time to progression (months)  
(n = 61)
6.75 months
Median overall survival (months) (n = 81) 13 months
CR, complete response; MPM, malignant pleural mesothelioma; OS, overall survival; PR, partial response; RECIST, 
Response Evaluation Criteria in Solid Tumors; SD, stable disease; TTP, time to progression.
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were also analyzed (including the highest tertile and highest 
quartile), but statistical significance was still not reached. The 
reason why we did not observe statistically significant differ-
ences in our study is not entirely clear. One potential expla-
nation could be differences in antibodies or technique. We 
view this as unlikely for the TS results, as all four studies (see 
Table 3) used the same anti-TS antibody clone (TS106) and 
three of the four studies used the antibody at the same dilu-
tion (1:100). It is possible we would have reached significance 
with larger numbers of patients.
Given this limitation in using TS expression alone, we 
also explored the utility of assessing the expression of FPGS. 
In vitro studies15,16 have suggested that loss of FPGS activity 
may lead to Pem resistance in cell lines because of decreased 
intracellular availability of the active poly-glutamated form of 
Pem. A recent study suggests there may be some predictive 
value in FPGS levels in MPM.13 In that study, the median 
FPGS H-score was 230 – a relatively high value because 
300 is the maximal score. High FPGS (greater than median) 
expression was associated with response rate and DCR, but not 
TABLE 2.  Outcomes of Patients with MPM According to Biomarker Expression
Biomarker Disease control rate Median TTP Median OS
TS HScore (median 105) n = 56 n = 76
Below the median (n = 35) 68.6 8 months 14 months
Above the median (n = 43) 72.1 6 months 11.25 months
(p) (0.73) (0.93) (0.59)
FPGS HScore (median 120) n = 54 n = 74
Below the mean 69.4 7 months 13.75 months
Above the mean 70.0 6 months 11 months
(p) (0.95) (0.77) (0.43)
FPGS/TS ratio (median 1.17) n = 53 n = 73
Below the mean 64.9 6 months 12 months
Above the mean 76.3 7.5 months 13 months
(p) (0.27) (0.10) (0.43)
FPGS, folyl-polyglutamate synthase; MPM, malignant pleural mesothelioma; OS, overall survival; TS, thymidylate synthase; 
TTP, time to progression.
TABLE 3.  Comparison of studies assessing TS as predictor of Pemetrexed efficacy in MPM
Righi (2010)11 Zucali (2011)12 Christoph (2012)13 Current study
Study design Single institution 
Observational - Retrospective
Single institution 
Observational – Retrospective
Single institution 
Observational - Retrospective
Multicenter 
Observational - Retrospective
Number of subjects 60 99 84 85
Primary end point Association between TS and 
ERCC1 with TTP and OS in 
pts treated with Pem and Cis 
respectively
Association between TS and 
ERCC1 with PFS, OS and DCR 
in pts treated with Pem and Cis 
respectively
Association between TS and 
FPGS expression and Pem 
efficacy (PFS, OS, DCR)
Association between TS and FPGS 
expression and Pem Efficacy 
(TTP, OS, DCR)
ASntibody type TS: TS106, (dilution 1:100); 
Zymed, San Francisco, CA 
ERCC: clone 8F1, dilution 
1:100; LabVision, Fremont, 
CA
TS: TS106, (dilution 1:100), 
DAKO 
ERCC1: clone 8F1, dilution 
1:50, Santa Cruz Biotechnology
TS: TS106 antibody (dilution 
1:10), Invitrogen, Inc., 
Carlsbad, CAF 
PGS: (dilution 1:20), Spring 
Bioscience, Inc., Pleasanton, 
CA
TS: TS106 (Invitrogen) at a dilution 
of 1:100, Zymed, San Francisco, 
CA 
FPGS: (dilution1:1500), 
Eli-Lilly, Indianapolis, IN
Variables measured TS and ERCC1 expression 
measured by IHC and rt-PCR
TS and ERCC1 expression 
measured by IHC and rt-PCR
TS and FPGS expression 
measured by IHC only
TS and FPGS expression measured 
by IHC only
Cutoff used  
(H score)
Median H score (90) and lower 
Tertile (60)
Median H score (21) Median H score  
(TS: 210  
FPGS: 230)
Median H score  
(TS: 105 
FPGS: 120)
Clinical 
characteristics
TTP – 10 months 
OS – 20.9 months 
Epithelial: 83%
PFS – 7 months 
OS – 13 months 
Epithelial: 92%
PFS – 7.6 mo 
OS: 23.3 moEpithelial: 86%
TTP – 6.5 monthsOS – 13 
monthsEpithelial: 70%
Findings TS but not ERCC1 expression 
was associated with TTP and 
OS
TS but not ERCC1 expression was 
associated with PFS, OS and 
DCR.
FPGS was associated with 
PFS, OR and DCR but not 
OS 
TS was associated with OS 
but not with PFS, OR or 
DCR
No association between marker 
expression (TS and FPGS) and 
either TTP, OS or DCR.
Cis: cisplatin; DCR: Disease control rate (complete response + partial response + stable disease); FPGS: folyl-polyglutamate synthase; MPM, malignant pleural mesothelioma; OR: 
Objective response (complete response plus partial response); OS: overall survival; Pem: Pemetrexed; TS: Thymidylate synthase; TTP: time to progression.
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OS. However, as shown in Table 2, we detected no association 
between FPGS expression and Pem efficacy. Of note, our 
median H-score was much lower at 120. We also determined if 
a higher FPGS/TS ratio (i.e., high(er) FPGS with low(er) TS) 
would correlate with improved outcome on Pem. We noted a 
trend towards increased TTP (p = 0.10) with higher FPGS/TS 
ratios, but not with OS (p = 0.43). Again, other cutoffs beside 
the median score were analyzed, but statistical significance 
was not achieved. Consistent with our clinical findings, we 
did not find an association between thein vitro Pem sensitivity 
(measured as the IC
50
 value) of several mesothelioma cell lines 
with TS or FPGS expression as measured by immunoblotting. 
One explanation for the discrepant results may be that we used 
an antibody different from that used in the Christoph study13.
The main limitation of this study was its retrospective 
observational design. Although stage is predictive of survival, 
this information was not available in the majority of patients 
and therefore could not be included in our survival analysis as 
a possible confounder. We also did not have baseline data on 
performance status or weight loss. The retrospective nature of 
our study made measurements of radiographic response and 
TTP less accurate because these were obtained as part of rou-
tine clinical care and not as part of a formal study protocol. 
Although we limited our analysis to patients who received a 
Pem-containing regimen in the first-line setting, some patients 
went on to receive second line therapies after disease progres-
sion; although benefits from second line therapy have never 
been proven in randomized phase III studies, it is conceivable 
that subsequent treatment could have influenced OS. We were 
also careful to exclude patients who received “adjuvant” che-
motherapy for similar reasons, because these patients, by and 
large, were likely to have earlier stage disease, better overall 
survival, and no “measurable” tumor after resection.
Even with these limitations in mind, the most important 
implication of this study relates to the issue of “statistical” 
versus “clinical” utility of a test. Specifically, even if TS levels 
ultimately prove to have a statistical association with response 
and survival in patients with MPM treated with Pem, it seems 
doubtful this association would have any true clinical utility. 
This translates to a broader clinical question: should TS levels 
be used to decide whether Pem should be administered to a 
specific MPM patient? This is an important issue, because a 
number of companies are already actively marketing tests to 
clinicians to measure TS mRNA or protein expression levels 
in tumors with the obvious, but unstated, implication that this 
information should be used in therapeutic decision-making. 
In addition, many clinicians have already made the “leap of 
faith” that TS levels do, in fact, predict benefit to Pem, both 
in MPM and in NSCLC, and are using these tests accordingly.
We believe our data indicate that TS expression levels 
should not be used in such decisions. First, the measurement 
of TS using IHC is inherently imprecise and rather subjective, 
even for trained academic lung pathologists. Each of the three 
studies found a different median H-score value for TS ranging 
from 21 (an extremely low value) to 210 (an extremely high 
value). It is unclear which value should be chosen as a cutoff. 
Carefully standardized positive and negative controls must be 
used with each staining run. Even with these controls, detect-
ing small differences is difficult. Reliably and reproducibly 
differentiating an H-score of 90 (a “low” value) and 130 (a 
“high” value) is challenging (Fig. 1). As a second example, in 
the Christoph study,13 the median FPGS H-score for respond-
ers was 255 and for non-responders was 220, again a very 
small difference to discern. Secondly, and perhaps even more 
importantly, even if an H-score can be reliably determined, 
the sensitivity and specificity of the test appears to be poor. 
This is shown in Figure 2, where we have plotted individual 
H-score values versus disease control status. Clearly, the over-
lap between groups precludes any meaningful prediction at 
the individual patient level. Accordingly, there were some 
patients with very low H-scores who did not respond to ther-
apy, just as there were some patients with very high H-scores 
whose disease was controlled. This key representation of the 
frequency distributions of H-scores has not been shown in any 
of the other manuscripts.
In summary, although other data suggest that TS and 
FPGS expression might be potential markers of Pem efficacy 
in patients with MPM in a “statistical setting”, our study indi-
cates that these markers lack sufficient predictive value in an 
individual patient to be used to guide clinical decisions. In 
fact, basic demographic factors, such as histology and age, are 
more predictive. Before TS and FPGS expression are used to 
make treatment selections, additional data are needed. Ideally, 
a prospective observational study with predetermined diag-
nostic criteria and standardized treatment, outcome measure-
ments and follow-up would need to be performed. If positive, 
a prospective trial randomizing patients to treatment based on 
TS and/or FPGS levels would need to be conducted to show 
increased efficacy. Until then, we do not recommend the use 
of these markers as determinants of therapy in the clinical 
setting.
ACkNOwLEDGMENTS
The authors thank Guanjun Cheng, MD, Jennifer 
Wheaton, BS, Jing Sun, MD, and Patrizia Morbini MD 
PhD. This work was partially supported by an NIEHS 
funded Environmental Health Sciences Core Center grant 
P30-ES013508 (S.M.A.) and NHLBI T32 HL07586 (D.S.L.).
REFERENCES
 1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of peme-
trexed in combination with cisplatin versus cisplatin alone in patients 
with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636–2644.
 2. Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther 
2005;27:1343–1382.
 3. Giovannetti E, Backus HH, Wouters D, et al. Changes in the status of p53 
affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering 
TS levels. Br J Cancer 2007;96:769–775.
 4. Longley DB, Ferguson PR, Boyer J, et al. Characterization of a 
thymidylate synthase (TS)-inducible cell line: a model system for 
studying sensitivity to TS- and non-TS-targeted chemotherapies. Clin 
Cancer Res 2001;7:3533–3539.
 5. Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters 
GJ. Induction of resistance to the multitargeted antifolate Pemetrexed 
(ALIMTA) in WiDr human colon cancer cells is associated with thymi-
dylate synthase overexpression. Biochem Pharmacol 2003;66:431–438.
 6. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of peme-
trexed according to NSCLC histology: a review of two Phase III studies. 
Oncologist 2009;14:253–263.
 7. Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology 
interaction analyses in three phase III trials show superiority of 
477Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 8, Number 4, April 2013 Thymidylate Synthase and Folyl-Polyglutamate Synthase (FPGS)
pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 
2011;6:64–70.
 8. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus 
best supportive care versus placebo plus best supportive care for non-
small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 
2009;374:1432–1440.
 9. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the 
lung compared with other histotypes shows higher messenger RNA and 
protein levels for thymidylate synthase. Cancer 2006;107:1589–1596.
 10. Sun JM, Han J, Ahn JS, Park K, Ahn MJ. Significance of thymidylate 
synthase and thyroid transcription factor 1 expression in patients with 
nonsquamous non-small cell lung cancer treated with pemetrexed-based 
chemotherapy. J Thorac Oncol 2011;6:1392–1399.
 11. Righi L, Papotti MG, Ceppi P, et al. Thymidylate synthase but not exci-
sion repair cross-complementation group 1 tumor expression predicts 
outcome in patients with malignant pleural mesothelioma treated with 
pemetrexed-based chemotherapy. J Clin Oncol 2010;28:1534–1539.
 12. Zucali PA, Giovannetti E, Destro A, et al. Thymidylate synthase and exci-
sion repair cross-complementing group-1 as predictors of responsive-
ness in mesothelioma patients treated with pemetrexed/carboplatin. Clin 
Cancer Res 2011;17:2581–2590.
 13. Christoph DC, Asuncion BR, Mascaux C, et al. Folylpoly-glutamate syn-
thetase expression is associated with tumor response and outcome from 
pemetrexed-based chemotherapy in malignant pleural mesothelioma. J 
Thorac Oncol 2012;7:1440–1448.
 14. Hanauske AR, Eismann U, Oberschmidt O, et al. In vitro chemosensitiv-
ity of freshly explanted tumor cells to pemetrexed is correlated with target 
gene expression. Invest New Drugs 2007;25:417–423.
 15. Liani E, Rothem L, Bunni MA, Smith CA, Jansen G, Assaraf YG. Loss of 
folylpoly-gamma-glutamate synthetase activity is a dominant mechanism 
of resistance to polyglutamylation-dependent novel antifolates in multiple 
human leukemia sublines. Int J Cancer 2003;103:587–599.
 16. Cho RC, Cole PD, Sohn KJ, et al. Effects of folate and folylpolyglutamyl 
synthase modulation on chemosensitivity of breast cancer cells. Mol 
Cancer Ther 2007;6:2909–2920.
 17. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of 
response in malignant pleural mesothelioma. Ann Oncol 2004;15:257–260.
 18. Dotzlaf J, Carpenter J, Luo S, et al. Derivation and characterization of 
monoclonal antibodies against human folypolyglutamate synthetase. 
Hybridoma (Larchmt) 2007;26:155–161.
 19. Ishibashi H, Suzuki T, Suzuki S, et al. Sex steroid hormone receptors in 
human thymoma. J Clin Endocrinol Metab 2003;88:2309–2317.
 20. Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and dihy-
drofolate reductase expression in non-small cell lung carcinoma: 
the association with treatment efficacy of pemetrexed. Lung Cancer 
2011;74:132–138.
